Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at *https://www.federalreserve.gov/foia/request.htm.* Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than June 4, 2025.

A. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001. Comments can also be sent electronically to *KCApplicationComments@kc.frb.org:*

1. *Regent Capital Corporation, Nowata, Oklahoma, through its subsidiary, DLP Acquisition Corporation, Tulsa, Oklahoma;* to merge with DLP Bancshares, Inc., Saint Augustine, Florida, and thereby indirectly acquire DLP Bank, Starke, Florida.

B. Federal Reserve Bank of Dallas (Lindsey Wieck, Director, Mergers & Acquisitions) 2200 North Pearl Street, Dallas, Texas 75201–2272. Comments can also be sent electronically to *Comments.applications@dal.frb.org:*

1. *2011 TCRT, Ford Ultimate Management II, LLC, Ford Management II, L.P., GJF Financial Management II, LLC, Ford Family Investment, LP, Ford Financial Fund II, L.P., EB Acquisition Company LLC, Ford Management III, L.P., Ford Financial Fund III, L.P., and EB Acquisition Company II LLC, all of University Park, Texas;* to acquire voting shares of HomeStreet, Inc., and thereby indirectly aquire voting shares of HomeStreet Bank, both of Seattle, Washington.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2025–07781 Filed 5–2–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Children and Families Administration

[OMB #: 0970–0166]

Proposed Information Collection Activity; National Directory of New Hires

AGENCY: Office of Child Support Services, Administration for Children and Families, U.S. Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Office of Child Support Services (OCSS), Administration for Children and Families (ACF), is requesting the Office of Management and Budget (OMB) to approve the National Directory of New Hires (NDNH), with minor changes to the Multistate Employer Registration form, for an additional three years. The current OMB approval expires July 31, 2025.

DATES: *Comments due* July 7, 2025. In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

ADDRESSES: You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov.* Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The NDNH is a federally mandated repository of employment and wage information. The information maintained in the NDNH is collected electronically and used for authorized purposes. State child support agencies use the NDNH information to locate a parent living or working in a different State and to take appropriate interstate actions to establish, modify, or enforce a child support order. Specific State and Federal agencies also use NDNH information for authorized purposes to help administer certain programs, prevent overpayments, detect fraud, assess benefits, and recover funds, as provided under 42 U.S.C. 653(i)(1). OCSS changed the unconventional date format to a standard format in the NDNH record specifications and changed the Multistate Employer Registration Form to revise language, update links, and remove the option to submit it by mail.

Respondents: Employers, State Child Support Agencies, and State Workforce Agencies.

ANNUAL BURDEN ESTIMATES

Instrument	Annual number of respondents	Annual number of responses per respondent	Average annual burden hours per response	Annual burden hours
New Hire: Employers Reporting Manually	5,667,878	1.56	.025	221,047.24
New Hire: Employers Reporting Electronically	626,726	126.80	.00028	22,251.28
New Hire: States	54	163,513.97	.017	150,105.82
Quarterly Wage and Unemployment Insurance	53	28.00	.00028	0.42
Multistate Employer Registration Form	1,555	1.00	.05	77.75

Estimated Total Annual Burden Hours: 393,482.51.

Comments: The U.S. Department of Health and Human Services specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or

other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: 42 U.S.C. 653A(b)(1)(A) and (B); 42 U.S.C. 653A(g)(2)(A) and (B), 42 U.S.C. 503(h)(1)(A); and 26 U.S.C. 3304(a)(16)(B)

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2025–07708 Filed 5–2–25; 8:45 am]

BILLING CODE 4184–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–5890]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Drug User Fee Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by June 4, 2025.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function. The OMB control number for this information collection is 0910–0727. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Generic Drug User Fee Program

OMB Control Number 0910–0727—Revision

This information collection helps support implementation of FDA's Generic Drug User Fee Program (GDUFA), most recently reauthorized September 30, 2022. It includes information collections discussed in the document, ''GDUFA Reauthorization Performance Goals And Program Enhancements Fiscal Years 2023–2027,'' commonly referred to as the ''Goals Letter'' or ''Commitment Letter.'' The Commitment Letter represents the product of FDA discussions with the regulated industry and public stakeholders, as mandated by Congress. The Goals Letter identifies current GDUFA program objectives and general procedures for communicating with FDA. Agency guidance, as outlined in the Goals Letter, are utilized in the information collection. All Agency guidance documents are issued consistent with our Good Guidance Practice regulations (21 CFR 10.115), which provide for public comment at any time, as well as regulatory authority found in 21 CFR 314.445 (Guidance documents), currently approved in OMB control number 0910–0001.

The information collection also includes Form FDA 3974, the Generic Drug User Fee Cover Sheet and associated instructions, available for download at *https://userfees.fda.gov/OA_HTML/GDUFAFacilityCScreation.pdf.* Form FDA 3974 is used to provide a uniform format for the submission of information necessary to account for and track user fees, and to determine the amount of the fee required.

As we communicate on our website, potential applicants are encouraged to contact the FDA Generic Drugs Program with questions at any point in their development and application preparation processes. We have revised the information collection to include the submission of ''controlled correspondence'' within the scope of activity, including covered product authorizations (CPAs) provided for under the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act) (Pub. L. 116–94). Historically, and under the terms of the GDUFA, a controlled correspondence may be submitted by or on behalf of a generic drug manufacturer or related industry prior to submitting an abbreviated new drug application (ANDA). To provide respondents with assistance regarding the submission of controlled correspondence, we continue to develop and issue topic-specific Agency guidance, including the following documents:

- Controlled Correspondence Related to Generic Drug Development (Controlled Correspondence Guidance) (*https://www.fda.gov/media/164111/download,* March 2024).
- Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa,* February 2023).
- Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry,* October 2022).
- Competitive Generic Therapies Guidance (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies,* October 2022).
- Cover Letter Attachments for Controlled Correspondences and ANDA Submissions (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cover-letter-attachments-controlled-correspondences-and-anda-submissions,* June 2023).
- How to Obtain Covered Product Authorization (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization,* September 2022).

Each guidance document may be downloaded from our website where we maintain a searchable database at *https://www.fda.gov/regulatory-information/search-fda-guidance-documents.*

In the **Federal Register** of January 14, 2025 (90 FR 3225), we published a 60-day notice soliciting comment on the proposed collection of information. Two comments were received, one pertaining to product pricing and the other pertaining to plant-based ingredients. FDA appreciates these public comments; however, neither is responsive to the four information collection topics solicited under 5 CFR 1320.8(d) and therefore not discussed in this notice. We have made no adjustments in our estimated burden in response to the public comment.

We estimate the burden of this collection of information as follows: